Ailogeneic hematopoietic cell transplantation for malignant hematological diseases in patients older than 50 yers of g

Wu Xiaojin(吳小津，Dept Hematol，1st Affil Hosp Soochow Univ，Suzhou 215007)…∥Chin J Transplant.－2011，32(8).－485 ～487

Ailogeneic hematopoietic cell transplantation for malignant hematological diseases in patients older than 50 yers of g

Wu Xiaojin(吳小津，Dept Hematol，1st Affil Hosp Soochow Univ，Suzhou 215007)…∥Chin J Transplant.－2011，32(8).－485 ～487

ObjectiveTo investigate the efficiency and safety of allogeneic hematopoietic cell transplantation for malignant hematological diseases in patients older than 50 years of age.MethodsFrom May 2002 to January 2010，35 patients P ＞50 years with malignant hematological diseases received allogeneic hematopoietic cell transplantation.In 35 patients，18 patients were conditioned with non－myeloablative regimen and 17 patients with myeloablative regimen.The outcome，engraftment and prognosis of allogeneic hematopoietic cell transplantation were analyzed.ResultsThe hematopoetic reconstitution was achieved in 32 of 35 patients.The median time of granulocyte count exceeding 0.5 × 109/L was 12 days and that of platetet count exceeding 20×109/L was 17 days.The cumulative incidence of aGVHD was 48.6%，and 37.9%patients developed cGVHD.The estimate probability of cumulative survival at 5 years was 48.5%，The estimate probability of cumulative mortality rate was 51.5%，and the estimated transplant－related mortality was 22.9%.The relapse rate was 11.4%.There was significant difference except for the incidence of cGVHD.ConclusionAllogeneic hematopoietic cell transplantation may be appropriate for older patients with malignant hematological diseases.8 refs，1 fig.

(Authors)